Healthcare Industry News: radiopharmaceuticals
News Release - October 26, 2016
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate GrowthIncoming specialists to focus on Quality Control and Quality Assurance Aspects of Supply Chain
NEW YORK, Oct. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Maria Gomes Nunes, Dr. PH, to the position of Manager of QC/QA (Quality Control/Quality Assurance) and Laura Chen to the position of Senior Quality Assurance Specialist. These new hires will report to J.C. Simeon, Actinium’s recently hired Executive Director of Quality Assurance, as part of an ongoing expansion of the Company’s Supply Chain Team.
“We are excited to welcome Dr. Nunes and Ms. Chen to the Actinium team,” said Kaushik J. Dave, Actinium’s Chief Executive Officer. “The hiring of such high quality individuals shortly after onboarding J.C. Simeon gives me great confidence in our ability to attract the talent we require as we build out strong pre-commercialization capabilities for our phase 2 and phase 3 programs and also prepare for pipeline expansion.”
Dr. Nunes will be responsible for providing quality assurance/control oversight related to clinical products release activities at Actinium’s external contract manufacturing organizations and contract testing labs. Dr. Nunes has over twenty years of experience encompassing management of quality control groups, systems and processes, laboratory and analytical method development and compliance, oncology drug discovery and development of small molecules and biologics at companies such as Wyeth, Pfizer, ImClone Systems/Eli Lilly and Mesoblast. Dr. Nunes holds a Doctorate in Public Health from Columbia University and a B.S. in Biology from University of Lisbon, Portugal. Ms. Laura Chen joins Actinium from Pfizer, where she worked for 11 years in several quality assurance positions, culminating as Senior Associate QA, Biotech Quality Operations. Laura holds a Bachelor of Arts degree from Rutgers University and is currently pursuing a Certificate in Quality Assurance/Regulatory Affairs from Temple University.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Source: Actinium Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.